Disc Medicine (IRON) Interest Expenses (2020 - 2026)
Disc Medicine (IRON) reported Interest Expenses of $844000.0 for Q1 2026, down 5.91% year-over-year from $897000.0 in Q1 2025, and down 4.42% on a QoQ basis from $883000.0 in Q4 2025.
Disc Medicine (IRON) has 6 years of Interest Expenses data on file, last reported at $844000.0 in Q1 2026.
- Quarterly Interest Expenses fell 5.91% year-over-year to $844000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 141.93% YoY) and the FY2025 annual result came in at $3.6 million, up 530.59% from the prior year.
- Interest Expenses fell to $844000.0 in Q1 2026 per IRON's latest filing, from $883000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $917000.0 in Q3 2025 and bottomed at $48000.0 in Q2 2022.
- The 4-year median for Interest Expenses is $863500.0 (2025), against an average of $642125.0.
- The widest annual swing landed in 2022, when Interest Expenses slumped 96.43%; it then soared 54.37% in 2025.
- Tracing IRON's Interest Expenses over 4 years: stood at $48000.0 in 2022, then surged by 1091.67% to $572000.0 in 2024, then soared by 54.37% to $883000.0 in 2025, then slipped by 4.42% to $844000.0 in 2026.
- Per Business Quant, the three latest IRON Interest Expenses figures stand at $844000.0 (Q1 2026), $883000.0 (Q4 2025), and $917000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | 844,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 844,000.00 |
| Mar 31, 2026 | 844,000.00 |
| Dec 31, 2025 | 883,000.00 |
| Dec 31, 2025 | 883,000.00 |
| Sep 30, 2025 | 917,000.00 |
| Sep 30, 2025 | 917,000.00 |
| Jun 30, 2025 | 910,000.00 |
| Jun 30, 2025 | 910,000.00 |
| Mar 31, 2025 | 897,000.00 |
| Mar 31, 2025 | 897,000.00 |
| Dec 31, 2024 | 572,000.00 |
| Dec 31, 2024 | 572,000.00 |
| Jun 30, 2022 | 48,000.00 |
| Jun 30, 2022 | 48,000.00 |
| Mar 31, 2022 | 66,000.00 |
| Mar 31, 2022 | 66,000.00 |
| Dec 31, 2021 | 2.15 Mn |
| Dec 31, 2021 | 2.15 Mn |
| Sep 30, 2021 | 2,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 121,000.00 |
| Jun 30, 2021 | 121,000.00 |
| Mar 31, 2021 | 1.85 Mn |
| Mar 31, 2021 | 1.85 Mn |
| Dec 31, 2020 | 4.52 Mn |
| Dec 31, 2020 | 4.52 Mn |
| Sep 30, 2020 | 2.05 Mn |
| Sep 30, 2020 | 2.05 Mn |
| Jun 30, 2020 | 107,000.00 |
| Jun 30, 2020 | 107,000.00 |
| Mar 31, 2020 | 153,000.00 |
| Mar 31, 2020 | 153,000.00 |